Announcements Trials
Browse Landscape

Phase

Phase 1/2 5Phase 1 3

Status

Active not recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3Lymphoid 3Plasma cell 2Classical hematology 1

Conditions

Myelodysplastic Syndromes 6Lymphoma 4Hematologic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Multiple Myeloma 3Leukemia, Myeloid, Acute 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia 3Neoplasm, Residual 2Lymphoma, Non-Hodgkin 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Osteosarcoma 1Neurotoxicity Syndromes 1Neuroblastoma 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Melanoma 1Lymphoproliferative Disorders 1Lymphoma, B-Cell 1Lymphohistiocytosis, Hemophagocytic 1Lymphatic Diseases 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1Immunoproliferative Disorders 1Immune System Diseases 1

Interventions

Cyclophosphamide 52Cytarabine 49fludarabine phosphate 38fludarabine 32Filgrastim 30Etoposide 23Rituximab 19Azacitidine 17Whole-Body Irradiation 16Tacrolimus 14Peripheral Blood Stem Cell Transplantation 13Granulocyte Colony-Stimulating Factor 13Decitabine 13Clofarabine 13venetoclax 12Melphalan 12Antilymphocyte Serum 12Mycophenolic Acid 11Methotrexate 11Radiotherapy 10Mitoxantrone 10Daunorubicin 10Busulfan 10sargramostim 9aldesleukin 9Vincristine 9Sirolimus 9Topotecan 8Idarubicin 8Dexamethasone 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Leukemia × AP 1903 reagent × Clear all
NCT02477878 2022-07-12

Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant

Bellicum Pharmaceuticals

Phase 1 Active not recruiting
10 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Hematologic Neoplasms

NCT03459170 2022-07-12

Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

Bellicum Pharmaceuticals

Phase 1 Active not recruiting
15 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasm, Residual, Hematologic Neoplasms

NCT02786485 2020-10-05

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT

Bellicum Pharmaceuticals

Phase 1 Withdrawn
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡